|
我们还得清醒，所有这些突破，这些发现，这些里程碑，这些药物，这些设备，有几项是我们的原创。我们有关TTT、PDT、曲安奈德或激光治疗CNV的临床研究有几项是多中心随机双盲对照试验研究？甚至概念，无论是CNV的分型，无论是RAP，PCV；甚至对CNV的翻译，是叫脉络膜新生血管，还是脉络膜新生血管膜或脉络膜新生血管形成；甚至AMD是称之为年龄相关性黄斑变性，还是老年黄斑变性，还是增龄性黄斑变性等等，对于如此这类最基本的概念，我们至今并没有统一或者明确。但这也并不妨碍我们的前进步伐。这些正好是我们要为之努力的方向。
路漫漫其修远兮，吾将上下而求索！
然而，我们仍然有足够的理由乐观，随着全球化信息化步伐，随着生物科技的日新月异的进展，不可能完成的使命将会变得可能，就象VEGF抗体已经被用于CNV的治疗，就象小干扰RNA技术，就在几年前，这还是一个实验室的概念，却竟然进入了III期临床试验，要真正地用于CNV的治疗了。
让我借用伟大的英格兰诗人雪莱在他的著名的《西风颂》的诗句：if winter comes, can spring be far behind?
参考文献
1. Macular Photocoagulation Study Group: Argon laser photocoagulation for senile macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol 100: 912-918, 1982.
2 Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular
lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220–31.
3.Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993 Jun 15;115(6):786-91.
4.Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol. 1994 Apr;112(4):489-99.
5.Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of occult choroidal neovascularization. Ophthalmology. 1994 ,101(10):1727-35; discussion 1735-1737.
6.Pece A, Introini U, Bolognesi G, et al. Indocyanine green angiography (ICGA) in age-related macular degeneration with occult CNV. Ophthalmologica. 1998;212(5):295-300
7.Shiraga F, Ojima Y, Matsuo T, et al. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 1998 Apr;105(4):662-669.
8.Youssfi-Rich A, Clement-Fernandez F, Garcia-Urtueta E, et al. Feeder vessel detection by means of dynamic indocyanine green angiography of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Soc Esp Oftalmol. 2006 Feb;81(2):79-84.
9.Freund KB, Yannuzzi LA, Spaide RF: Feeder vessel photocoagulation for subfoveal CNV. Ophthalmology 1998 ,105(12): 2164-2165
10.Reichel E, Berrocal AM, Ip M, et al.Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology. 1999,106(10):1908-14
11.Stolba U, Krebs I, Lamar PD, A, et al. Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial.Br J Ophthalmol. 2006 ,90(2):158-61
12.Algvere PV, Libert C, Lindgarde G, et al. Transpupillary thermotherapy of predominantly occult choroidal neovascularization in age-related macular degeneration with 12 months follow-up. Acta Ophthalmol Scand. 2003, 81(2):110-7
13.Atarashi T, Tamaki Y, Inoue Y, et al.Transpupillary thermotherapy for treatment of exudative age-related macular degeneration in Japanese patients. Eye. 2004 Jun;18(6):615-8
14.张承芬,李志清,董方田等.经瞳孔温热疗法治疗老年性黄斑变性合并中心凹下脉络膜新生血管. 中华眼底病杂志.2004,20,280-284
15.王光璐,彭晓燕.经瞳孔温热疗法治疗渗出型老年性黄斑变性的临床疗效观察.中华眼底病杂志,2002,18:180-183.
16.Gustavsson C, Agardh E.Transpupillary thermotherapy for occult subfoveal choroidal neovascularization: a 1-year, prospective randomized pilot study. Acta Ophthalmol Scand. 2005,83(2):148-53
17.Michels S, Schmidt-Erfurth U. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:2147–2154. 18.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: one-year results of 2 randomised clinical trials—TAP report. Arch Ophthalmol 1999;117:1329–45.
19. VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration:two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-- Verteporfin in Photodynamic therapy Report 2. AM J Ophthalmol, 2001, 131:541-560.
20.严密, 陆方,张军军,等.光动力疗法治疗渗出型老年性黄斑变性的初步报告. 中华眼底病杂志, 2001,16:213-216.
21.何守志，李晓隙，王玮，等。光动力疗法治疗老年性黄斑变性合并脉络膜新生血管的临床观察。中华眼底病杂志，2002，18；171-174.
22.张美霞，陆方，严密，等。光动力疗法治疗渗出型老年性黄斑变性四年临床观察总结。中华眼底病杂志，2004，20；275-279.
23.Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004, 351:2805–2816.7. 24.Chakravarthy U, Soubrane G, Bandello F,et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br. J. Ophthalmol, 2006, 90;1188-1196
25．Heier JS, Antoszyk AN, Pavan PR, Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006,113(4):642.e1-4.
26.Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Ophthalmol, 2006, 113:2002-2011
27.Rosenfeld PJ, Andrew A, Moshfeghi AA, et al. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331–5. 28.Shah CP, Hsu J, Garg SJ, et al. Retinal pigment epithelial tear after intravitreal bevacizumab injection。Am J Ophthalmol. 2006 Dec;142(6):1070-1071
29.Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol, 2003, 195:241–248.
30. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol, 2003,121:667-673
31.Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol, 2004, 122:218-222
32. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging, 2003, 34:386-390
33.郑秀云 党光福 王超庆 曲安奈德玻璃体腔内注射诱发眼内炎二例 《中华眼底病杂志》 2005 / 21 / 4
34.Schmidt-Erfurth U, Michels S, Michels R, et al. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol. 2005 Jul-Aug;15(4):482-5
35.Slakter JS, Bochow T, D’Amico DJ, et al. Anecortave Acetate Clinical Study Group. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology, 2006, 113:3–13.
36.Miskala PH, Bass EB, Bressler NM, Submacular Surgery Trials (SST) Research Group, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no 12. Ophthalmology 2004;111:1981–92.
37.Schmidt JC, Rodrigues EB, Meyer CH, et al. Is membrane extraction in cases of exudative agerelated macular degeneration still up-to-date? A 4-year resume. Ophthalmologica 2003;217:401–7.
38.董方田,张承芬,费佩芬,等. 黄斑下脉络膜新生血管膜的手术治疗及随访观察. 中华眼科杂志,1997,33: 251-254
39.Kroll P, Meyer C H.What is the best treatment for AMD? Br J Ophthalmol 2006;90:128–130,
40.Binder S, Krebs I, Hilgers RD, et al. Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial. Invest Ophthalmol Vis Sci 2004;45:4151–60.
41.Van Meurs JC, Van Den Biesen PR. Autologous retinal pigment epithelium and choroid translocation in patients with exudative agerelated macular degeneration: short-term follow-up. Am J Ophthalmol 2003;136:688–95. 22
42.Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:313–25.
43.Lai JC, Lapolice DJ, Stinnett SS, et al. Visual outcomes following macular translocation with 360-degree peripheral retinectomy. Arch Ophthalmol 2002;120:1317–24.
44.Heier JS, Boyer DS, Ciulla TA,,et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.Arch Ophthalmol. 2006 Nov;124(11):1532-42.
45.Liggett PE, Colina J, Chaudhry NA,et al. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol. 2006,42(6):1072-4.
46.Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006, 19(3):361-72.
47.周海英，张风，高丽琴等. 应用血啉甲醚的光动力学疗法治疗实验性虹膜新生血管. 眼科研究, 2005 , 23(6):
<< 上一页 [11] [12] |
网友评论：（只显示最新10条。评论内容只代表网友观点，与本站立场无关！）